^
    Back
    Association details:
    Biomarker:AR expression
    Cancer:Breast Cancer
    Drug:dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation

    Excerpt:
    We found that AR-positive breast cancer cell lines are much more sensitive to NVP-BEZ235 compared with AR-negative cells, regardless of PTEN or PI3KCA status.
    DOI:
    10.1158/1535-7163.MCT-13-0655